EXKIVITY (mobocertinib) TAKEDA Indications: EXKIVITY is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, ...

COLUMVI (glofitamab-gxbm) ROCHE Indications: COLUMVI is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from foll...

Trodelvy (sacituzumab govitecan) Gilead Presentation: Each vial contains 180 mg of Sacituzumab govitecan. Off-white to yellowish lyophilized powder in a single-dose vial. Indications: Trodelvy is indicated for the treatment of adult patients wit...

Exkivity® ( mobocertinib ) 1-3 Takeda Mobocertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that selectively inhibits and irreversibly binds to EGFR exon 20 insertion mutations at lower concentrations than Wild type (...